VNLS Vernalis Plc ADS (MM)

WINNERSH, U.K., Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VER) (NASDAQ:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief Executive Officer, and Tony Weir, Chief Financial Officer, will participate in the UBS Global Life Sciences Conference to be held September 25-28, 2006 at the Grand Hyatt in New York City. Mr. Sturge is scheduled to present an overview of the Company's business activities and product pipeline at 8:00 AM Eastern time on Tuesday, September 26, 2006. To listen to the audio webcast of the presentation, please visit: http://www.ibb.ubs.com/ About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has two marketed products, Frova(R) and Apokyn(R), and a development pipeline focused on neurology and central nervous system disorders. The company has seven products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Serono. Vernalis has established a US commercial operation to promote Apokyn(R) and co-promote Frova(R) alongside its North American licensing partner, Endo Pharmaceuticals, progressing the company towards its goal of becoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceutical company. For further information about Vernalis, please visit http://www.vernalis.com/. Enquiries: Vernalis plc +44 (0) 118 977 3133 Simon Sturge, Chief Executive Officer Tony Weir, Chief Financial Officer Julia Wilson, Head of Corporate Communications Lazar Partners Ltd Gregory Gin 212-867-1762 Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products and including that of Frova(R) for menstrual migraine, the Company's ability to find partners for the development and commercialisation of its products, the benefits of re-acquiring Frova(R) in North America and the partnership with Endo on the Company's liquidity and results of operations, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, including with respect to Frova(R) and the Company's other products, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of Frova(R) and other products, as well as the achievement of expected synergies from such transactions, the acceptance of Frova(R) and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions. DATASOURCE: Vernalis plc CONTACT: Simon Sturge, Chief Executive Officer, Tony Weir, Chief Financial Officer, or Julia Wilson, Head of Corporate Communications, +44-(0)118-977-3133, all of Vernalis plc; or Gregory Gin, Lazar Partners Ltd, +1-212-867-1762 Web site: http://www.vernalis.com/

Copyright